Top

Published in:

Open Access 01-12-2020 | Diabetes | Original investigation

Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles

Authors: Antonio J. Amor, Esmeralda Castelblanco, Marta Hernández, Marga Gimenez, Minerva Granado-Casas, Jesús Blanco, Berta Soldevila, Enric Esmatjes, Ignacio Conget, Nuria Alonso, Emilio Ortega, Didac Mauricio

Published in: Cardiovascular Diabetology | Issue 1/2020

Abstract

Background

Lipoprotein disturbances have been associated with increased cardiovascular disease (CVD) risk in type 1 diabetes mellitus (T1DM). We assessed the advanced lipoprotein profile in T1DM individuals, and analysed differences with non-diabetic counterparts.

Methods

This cross-sectional study involved 508 adults with T1DM and 347 controls, recruited from institutions in a Mediterranean region of Spain. Conventional and advanced (assessed by nuclear magnetic resonance [NMR] spectroscopy) lipoprotein profiles were analysed. Crude and adjusted (by age, sex, statin use, body mass index and leukocyte count) comparisons were performed.

Results

The median (interquartile range) age of the study participants was 45 (38–53) years, 48.2% were men. In the T1DM group, the median diabetes duration was 23 (16–31) years, and 8.1% and 40.2% of individuals had nephropathy and retinopathy, respectively. The proportion of participants with hypertension (29.5 vs. 9.2%), and statin use (45.7% vs. 8.1%) was higher in the T1DM vs. controls (p < 0.001). The T1DM group had a better conventional (all parameters, p < 0.001) and NMR-lipid profile than the control group. Thus, T1DM individuals showed lower concentrations of atherogenic lipoproteins (VLDL-particles and LDL-particles) and higher concentrations of anti-atherogenic lipoproteins (HDL-particles) vs. controls, even after adjusting for several confounders (p < 0.001 for all). While non-diabetic women had a more favourable lipid profile than non-diabetic men, women with T1DM had a similar concentration of LDL-particles compared to men with T1DM (1231 [1125–1383] vs. 1257 [1128–1383] nmol/L, p = 0.849), and a similar concentration of small-LDL-particles to non-diabetic women (672.8 [614.2–733.9] vs. 671.2 [593.5–761.4] nmol/L, respectively; p = 0.790). Finally, T1DM individuals showed higher discrepancies between NMR-LDL-particles and conventional LDL-cholesterol than non-diabetic subjects (prevalence of LDL-cholesterol < 100 mg/dL & LDL-particles > 1000 nmol/L: 38 vs. 21.2%; p < 0.001). All these differences were largely unchanged in participants without lipid-lowering drugs (T1DM, n = 275; controls, n = 317).

Conclusions

Overall, T1DM participants showed a more favourable conventional and NMR-lipid profile than controls. However, the NMR-assessment identified several lipoprotein derangements in LDL-particles among the T1DM population (higher discrepancies in NMR-LDL-particles vs. conventional LDL-cholesterol; a worse profile in T1DM women) that were overlooked in the conventional analysis. Further studies are needed to elucidate their role in the development of CVD in this population.

Available only for authorised users

Rawshani A, Sattar N, Franzén S, Rawshani A, Hattersley AT, Svensson A-M, Eliasson B, Gudbjörnsdottir S. Excess mortality and cardiovascular disease in young adults with type 1 diabetes in relation to age at onset: a nationwide, register-based cohort study. Lancet. 2018;392(10146):477–86. https://doi.org/10.1016/S0140-6736(18)31506-X.CrossRefPubMedPubMedCentral

Lind M, Svensson A-M, Kosiborod M, Gudbjörnsdottir S, Pivodic A, Wedel H, Dahlqvist S, Clements M, Rosengren A. Glycemic control and excess mortality in type 1 diabetes. N Engl J Med. 2014;371(21):1972–82. https://doi.org/10.1056/NEJMoa1408214.CrossRefPubMed

Amor AJ, Vinagre I, Valverde M, Pané A, Urquizu X, Meler E, López E, Quirós C, Giménez M, Codina L, Conget I, Barahona MJ, Perea V. Preeclampsia Is associated with increased preclinical carotid atherosclerosis in women with type 1 diabetes. J Clin Endocrinol Metab. 2020. https://doi.org/10.1210/clinem/dgz031.CrossRefPubMed

Carbonell M, Castelblanco E, Valldeperas X, Betriu À, Traveset A, Granado-Casas M, Hernández M, Vázquez F, Martín M, Rubinat E, Lecube A, Franch-Nadal J, Fernández E, Puig-Domingo M, Avogaro A, Alonso N, Mauricio D. Diabetic retinopathy is associated with the presence and burden of subclinical carotid atherosclerosis in type 1 diabetes. Cardiovasc Diabetol. 2018;17(1):66. https://doi.org/10.1186/s12933-018-0706-z.CrossRefPubMedPubMedCentral

de Ferranti SD, de Boer IH, Fonseca V, Fox CS, Golden SH, Lavie CJ, Magge SN, Marx N, McGuire DK, Orchard TJ, Zinman B, Eckel RH. Type 1 diabetes mellitus and cardiovascular disease: a Scientific Statement From the American Heart Association and American Diabetes Association. Diabetes Care. 2014;37(10):2843–63. https://doi.org/10.2337/dc14-1720.CrossRefPubMedPubMedCentral

Rawshani A, Rawshani A, Sattar N, Franzén S, McGuire DK, Eliasson B, Svensson AM, Zethelius B, Miftaraj M, Rosengren A, Gudbjörnsdottir S. Relative prognostic importance and optimal levels of risk factors for mortality and cardiovascular outcomes in type 1 diabetes mellitus. Circulation. 2019;139(16):1900–12. https://doi.org/10.1161/CIRCULATIONAHA.118.037454.CrossRefPubMed

Vaisar T, Kanter JE, Wimberger J, Irwin AD, Gauthier J, Wolfson E, Bahnam V, Wu I-H, Shah H, Keenan HA, Greenbaum CJ, King GL, Heinecke JW, Bornfeldt KE. High concentration of medium-sized HDL particles and enrichment in HDL paraoxonase 1 associate with protection from vascular complications in people with long-standing type 1 diabetes. Diabetes Care. 2019. https://doi.org/10.2337/dc19-0772.CrossRefPubMedPubMedCentral

Bebu I, Braffett BH, Orchard TJ, Lorenzi GM, Lachin JM, and the DCCT/EDIC Research Group. Mediation of the effect of glycemia on the risk of CVD outcomes in type 1 diabetes: the DCCT/EDIC Study. Diabetes Care. 2019. https://doi.org/10.2337/dc18-1613.CrossRefPubMedPubMedCentral

Diabetes Control and Complications Trial Research Group. Lipid and lipoprotein levels in patients with IDDM diabetes control and complication. Trial experience. The DCCT Research Group. Diabetes Care. 1992;15(7):886–94. https://doi.org/10.2337/diacare.15.7.886.CrossRef

10.

Maahs DM, Hokanson JE, Wang H, Kinney GL, Snell-Bergeon JK, East A, Bergman BC, Schauer IE, Rewers M, Eckel RH. Lipoprotein subfraction cholesterol distribution is proatherogenic in women with type 1 diabetes and insulin resistance. Diabetes. 2010;59(7):1771–9. https://doi.org/10.2337/db09-1626.CrossRefPubMedPubMedCentral

11.

Hughes TA, Calderon RM, Diaz S, Mendez AJ, Goldberg RB. Lipoprotein composition in patients with type 1 diabetes mellitus: impact of lipases and adipokines. J Diabetes Complications. 2016;30(4):657–68. https://doi.org/10.1016/j.jdiacomp.2016.01.018.CrossRefPubMed

12.

Brugnara L, Mallol R, Ribalta J, Vinaixa M, Murillo S, Casserras T, Guardiola M, Vallvé JC, Kalko SG, Correig X, Novials A. Improving assessment of lipoprotein profile in type 1 diabetes by 1H NMR spectroscopy. Zhang Y, ed. PLoS ONE. 2015;10(8):e0136348. https://doi.org/10.1371/journal.pone.0136348.CrossRefPubMedPubMedCentral

13.

Bervoets L, Massa G, Guedens W, Louis E, Noben J-P, Adriaensens P. Metabolic profiling of type 1 diabetes mellitus in children and adolescents: a case–control study. Diabetol Metab Syndr. 2017;9(1):48. https://doi.org/10.1186/s13098-017-0246-9.CrossRefPubMedPubMedCentral

14.

Llauradó G, Amigó N, Cano A, Ballesta S, Albert L, Mazarico I, Fernández-Veledo S, Pedro-Botet J, Vendrell J, González-Clemente J-M. Specific nuclear magnetic resonance lipoprotein subclass profiles and central arterial stiffness in type 1 diabetes mellitus: a case control study. J Clin Med. 2019;8(11):1875. https://doi.org/10.3390/jcm8111875.CrossRefPubMedCentral

15.

Gourgari E, Playford MP, Campia U, Dey AK, Cogen F, Gubb-Weiser S, Mete M, Desale S, Sampson M, Taylor A, Rother KI, Remaley AT, Mehta NN. Low cholesterol efflux capacity and abnormal lipoprotein particles in youth with type 1 diabetes: a case control study. Cardiovasc Diabetol. 2018;17(1):158. https://doi.org/10.1186/s12933-018-0802-0.CrossRefPubMedPubMedCentral

16.

Colhoun HM, Otvos JD, Rubens MB, Taskinen MR, Underwood SR, Fuller JH. Lipoprotein subclasses and particle sizes and their relationship with coronary artery calcification in men and women with and without type 1 diabetes. Diabetes. 2002;51(6):1949–56. https://doi.org/10.2337/diabetes.51.6.1949.CrossRefPubMed

17.

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111–88. https://doi.org/10.1093/eurheartj/ehz455.CrossRefPubMed

18.

Vilanova MB, Falguera M, Marsal JR, Rubinat E, Alcubierre N, Castelblanco E, Granado-Casas M, Miró N, Molló À, Mata-Cases M, Franch-Nadal J, Mauricio D. Prevalence, clinical features and risk assessment of pre-diabetes in Spain: the prospective Mollerussa cohort study. BMJ Open. 2017;7(6):e015158. https://doi.org/10.1136/bmjopen-2016-015158.CrossRefPubMedPubMedCentral

19.

Viñals C, Conget I, Pané A, Boswell L, Perea V, Blanco A, Ruiz S, Giménez M, Vinagre I, Esmatjes E, Ortega E, Amor A. Steno type 1 risk engine and preclinical atherosclerosis in Mediterranean individuals with type 1 diabetes. Diabetes Metab Res Rev. 2020. https://doi.org/10.1002/dmrr.3320.CrossRefPubMed

20.

Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, Braun LT, de Ferranti S, Faiella-Tommasino J, Forman DE, Goldberg R, Heidenreich PA, Hlatky MA, Jones DW, Lloyd-Jones D, Lopez-Pajares N, Ndumele CE, Orringer CE, Peralta CA, et al. AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. J Am Coll Cardiol. 2018. https://doi.org/10.1016/j.jacc.2018.11.003.CrossRefPubMed

21.

Alberti KGMM, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WPT, Loria CM, Smith SC. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; National heart, lung, and blood institute; American heart association; World heart federation. Int Circ. 2009;120(16):1640–5. https://doi.org/10.1161/CIRCULATIONAHA.109.192644.CrossRef

22.

Nordestgaard BG, Langlois MR, Langsted A, Chapman MJ, Aakre KM, Baum H, Borén J, Bruckert E, Catapano A, Cobbaert C, Collinson P, Descamps OS, Duff CJ, von Eckardstein A, Hammerer-Lercher A, Kamstrup PR, Kolovou G, Kronenberg F, Mora S, et al. Quantifying atherogenic lipoproteins for lipid-lowering strategies: consensus-based recommendations from EAS and EFLM. Atherosclerosis. 2020;294:46–61. https://doi.org/10.1016/j.atherosclerosis.2019.12.005.CrossRefPubMed

23.

Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, Feldman HI, Kusek JW, Eggers P, Van Lente F, Greene T, Coresh J, CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–12.PubMedPubMedCentral

24.

Bedogni G, Bellentani S, Miglioli L, Masutti F, Passalacqua M, Castiglione A, Tiribelli C. The Fatty Liver Index: a simple and accurate predictor of hepatic steatosis in the general population. BMC Gastroenterol. 2006;6(1):33. https://doi.org/10.1186/1471-230X-6-33.CrossRefPubMedPubMedCentral

25.

Dabelea D, D’Agostino RB, Mason CC, West N, Hamman RF, Mayer-Davis EJ, Maahs D, Klingensmith G, Knowler WC, Nadeau K. Development, validation and use of an insulin sensitivity score in youths with diabetes: the SEARCH for diabetes in youth study. Diabetologia. 2011;54(1):78–86. https://doi.org/10.1007/s00125-010-1911-9.CrossRefPubMed

26.

Mallol R, Amigó N, Rodríguez MA, Heras M, Vinaixa M, Plana N, Rock E, Ribalta J, Yanes O, Masana L, Correig X. Liposcale: a novel advanced lipoprotein test based on 2D diffusion-ordered 1H NMR spectroscopy. J Lipid Res. 2015;56(3):737–46. https://doi.org/10.1194/jlr.D050120.CrossRefPubMedPubMedCentral

27.

Amor AJ, Catalan M, Pérez A, Herreras Z, Pinyol M, Sala-Vila A, Cofán M, Gilabert R, Ros E, Ortega E. Nuclear magnetic resonance lipoprotein abnormalities in newly-diagnosed type 2 diabetes and their association with preclinical carotid atherosclerosis. Atherosclerosis. 2016;247:161–9. https://doi.org/10.1016/j.atherosclerosis.2016.02.014.CrossRefPubMed

28.

Amor AJ, Pinyol M, Solà E, Catalan M, Cofán M, Herreras Z, Amigó N, Gilabert R, Sala-Vila A, Ros E, Ortega E. Relationship between noninvasive scores of nonalcoholic fatty liver disease and nuclear magnetic resonance lipoprotein abnormalities: a focus on atherogenic dyslipidemia. J Clin Lipidol. 2017;11(2):551–561.e7. https://doi.org/10.1016/j.jacl.2017.02.001.CrossRefPubMed

29.

Gourgari E, Ma J, Playford MP, Mehta NN, Goldman R, Remaley AT, Gordon SM. Proteomic alterations of HDL in youth with type 1 diabetes and their associations with glycemic control: a case-control study. Cardiovasc Diabetol. 2019. https://doi.org/10.1186/s12933-019-0846-9.CrossRefPubMedPubMedCentral

30.

Damasceno NRT, Sala-Vila A, Cofán M, Pérez-Heras AM, Fitó M, Ruiz-Gutiérrez V, Martínez-González MÁ, Corella D, Arós F, Estruch R, Ros E. Mediterranean diet supplemented with nuts reduces waist circumference and shifts lipoprotein subfractions to a less atherogenic pattern in subjects at high cardiovascular risk. Atherosclerosis. 2013;230(2):347–53. https://doi.org/10.1016/j.atherosclerosis.2013.08.014.CrossRefPubMed

31.

Granado-Casas M, Alcubierre N, Martín M, Real J, Ramírez-Morros AM, Cuadrado M, Alonso N, Falguera M, Hernández M, Aguilera E, Lecube A, Castelblanco E, Puig-Domingo M, Mauricio D. Improved adherence to Mediterranean Diet in adults with type 1 diabetes mellitus. Eur J Nutr. 2019;58(6):2271–9. https://doi.org/10.1007/s00394-018-1777-z.CrossRefPubMed

32.

Huxley RR, Peters SAE, Mishra GD, Woodward M. Risk of all-cause mortality and vascular events in women versus men with type 1 diabetes: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2015;3(3):198–206. https://doi.org/10.1016/S2213-8587(14)70248-7.CrossRefPubMed

33.

Idzior-Walus B, Mattock MB, Solnica B, Stevens L, Fuller JH. Factors associated with plasma lipids and lipoproteins in Type 1 diabetes mellitus: the EURODIAB IDDM Complications Study. Diabet Med. 2001;18(10):786–96. https://doi.org/10.1046/j.0742-3071.2001.00571.x.CrossRefPubMed

34.

Bjornstad P, Eckel RH. Pathogenesis of lipid disorders in insulin resistance: a brief review. Curr Diab Rep. 2018;18(12):127. https://doi.org/10.1007/s11892-018-1101-6.CrossRefPubMedPubMedCentral

35.

Giuffrida FMA, Guedes AD, Rocco ER, Mory DB, Dualib P, Matos OS, Chaves-Fonseca RM, Cobas RA, Negrato CA, Gomes MB, Dib SA, Matheus A, Tannus L, Zajdenverg L, Rodacki M, de Araujo NBC, de Menezes Cordeiro M, Luescher JL, Berardo RS, et al. Heterogeneous behavior of lipids according to HbA1c levels undermines the plausibility of metabolic syndrome in type 1 diabetes: data from a nationwide multicenter survey. Cardiovasc Diabetol. 2012. https://doi.org/10.1186/1475-2840-11-156.CrossRefPubMedPubMedCentral

36.

Mäkinen V-P, Soininen P, Kangas AJ, Forsblom C, Tolonen N, Thorn LM, Viikari J, Raitakari OT, Savolainen M, Groop P-H, Ala-Korpela M, Finnish Diabetic Nephropathy Study Group. Triglyceride-cholesterol imbalance across lipoprotein subclasses predicts diabetic kidney disease and mortality in type 1 diabetes: the FinnDiane Study. J Intern Med. 2013;273(4):383–95. https://doi.org/10.1111/joim.12026.CrossRefPubMed

37.

Basu A, Jenkins AJ, Zhang Y, Stoner JA, Klein RL, Lopes-Virella MF, Garvey WT, Lyons TJ. Nuclear magnetic resonance-determined lipoprotein subclasses and carotid intima-media thickness in type 1 diabetes. Atherosclerosis. 2016;244:93–100. https://doi.org/10.1016/j.atherosclerosis.2015.10.106.CrossRefPubMed

38.

Nyström T, Holzmann MJ, Eliasson B, Svensson A-M, Sartipy U. Estimated glucose disposal rate predicts mortality in adults with type 1 diabetes. Diabetes Obes Metab. 2018;20(3):556–63. https://doi.org/10.1111/dom.13110.CrossRefPubMed

39.

Šimonienė D, Platūkiene A, Prakapienė E, Radzevičienė L, Veličkiene D. Insulin resistance in type 1 diabetes mellitus and its association with patient’s micro- and macrovascular complications, sex hormones, and other clinical data. Diabetes Ther. 2019. https://doi.org/10.1007/s13300-019-00729-5.CrossRefPubMedPubMedCentral

40.

Pané A, Conget I, Boswell L, Ruiz S, Viñals C, Perea V, Giménez M, Cofán M, Blanco J, Vinagre I, Esmatjes E, Ortega E, Amor AJ. Insulin resistance is associated with preclinical carotid atherosclerosis in patients with type 1 diabetes. Diabetes Metab Res Rev. 2020. https://doi.org/10.1002/dmrr.3323.CrossRefPubMed

41.

Jenkins AJ, Lyons TJ, Zheng D, Otvos JD, Lackland DT, McGee D, Garvey WT, Klein RL. Serum lipoproteins in the diabetes control and complications trial/epidemiology of diabetes intervention and complications cohort: associations with gender and glycemia. Diabetes Care. 2003;26(3):810–8. https://doi.org/10.2337/diacare.26.3.810.CrossRefPubMed

42.

Abed E, Labarbera B, Dvorak J, Zhang Y, Beck J, Talsania M. Prevalence of dyslipidemia and factors affecting dyslipidemia in young adults with type 1 diabetes: evaluation of statin prescribing. J Pediatr Endocrinol Metab. 2019;32(4):327–34. https://doi.org/10.1515/jpem-2018-0383.CrossRefPubMed

43.

Bojanin D, Vekic J, Milenkovic T, Vukovic R, Zeljkovic A, Stefanovic A, Janac J, Ivanisevic J, Mitrovic K, Miljkovic M, Spasojevic-Kalimanovska V. Association between proprotein convertase subtilisin/kexin 9 (PCSK9) and lipoprotein subclasses in children with type 1 diabetes mellitus: effects of glycemic control. Atherosclerosis. 2019;280:14–20. https://doi.org/10.1016/j.atherosclerosis.2018.11.020.CrossRefPubMed

44.

Ference BA, Ginsberg HN, Graham I, Ray KK, Packard CJ, Bruckert E, Hegele RA, Krauss RM, Raal FJ, Schunkert H, Watts GF, Borén J, Fazio S, Horton JD, Masana L, Nicholls SJ, Nordestgaard BG, van de Sluis B, Taskinen M-R, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38(32):2459–72. https://doi.org/10.1093/eurheartj/ehx144.CrossRefPubMedPubMedCentral

45.

Rawshani A, Rawshani A, Franzén S, Eliasson B, Svensson A-M, Miftaraj M, McGuire DK, Sattar N, Rosengren A, Gudbjörnsdottir S. Range of risk factor levels: control, mortality, and cardiovascular outcomes in type 1 diabetes mellitus. Circulation. 2017;135(16):1522–31. https://doi.org/10.1161/CIRCULATIONAHA.116.025961.CrossRefPubMedPubMedCentral

46.

Svanteson M, Holte KB, Haig Y, Kløw NE, Berg TJ. Coronary plaque characteristics and epicardial fat tissue in long term survivors of type 1 diabetes identified by coronary computed tomography angiography. Cardiovasc Diabetol. 2019. https://doi.org/10.1186/s12933-019-0861-x.CrossRefPubMedPubMedCentral

47.

Bebu I, Braffett BH, Pop-Busui R, Orchard TJ, Nathan DM, Lachin JM, DCCT/EDIC Research Group. The relationship of blood glucose with cardiovascular disease is mediated over time by traditional risk factors in type 1 diabetes: the DCCT/EDIC study. Diabetologia. 2017;60(10):2084–91. https://doi.org/10.1007/s00125-017-4374-4.CrossRefPubMedPubMedCentral

48.

Pichler G, Amigo N, Tellez-Plaza M, Pardo-Cea MA, Dominguez-Lucas A, Marrachelli VG, Monleon D, Martin-Escudero JC, Ascaso JF, Chaves FJ, Carmena R, Redon J. LDL particle size and composition and incident cardiovascular disease in a South-European population: the Hortega-Liposcale Follow-up Study. Int J Cardiol. 2018;264:172–8. https://doi.org/10.1016/j.ijcard.2018.03.128.CrossRefPubMed

49.

Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH, Goff DC. Clinical implications of discordance between low-density lipoprotein cholesterol and particle number. J Clin Lipidol. 2011;5(2):105–13. https://doi.org/10.1016/j.jacl.2011.02.001.CrossRefPubMedPubMedCentral

50.

Mora S, Buring JE, Ridker PM. Discordance of low-density lipoprotein (LDL) cholesterol with alternative LDL-related measures and future coronary events. Circulation. 2014;129(5):553–61. https://doi.org/10.1161/CIRCULATIONAHA.113.005873.CrossRefPubMed

51.

Hagensen MK, Mortensen MB, Kjolby M, Stillits NL, Steffensen LB, Bentzon JF. Type 1 diabetes increases retention of low-density lipoprotein in the atherosclerosis-prone area of the murine aorta. Atherosclerosis. 2017;263:7–14. https://doi.org/10.1016/j.atherosclerosis.2017.05.019.CrossRefPubMed

52.

Mallol R, Rodriguez MA, Brezmes J, Masana L, Correig X. Human serum/plasma lipoprotein analysis by NMR: application to the study of diabetic dyslipidemia. Prog Nucl Magn Reson Spectrosc. 2013;70:1–24. https://doi.org/10.1016/j.pnmrs.2012.09.001.CrossRefPubMed

53.

Vergès B. Dyslipidemia in type 1 diabetes: a masked danger. Trends Endocrinol Metab. 2020;31(6):422–34. https://doi.org/10.1016/j.tem.2020.01.015.CrossRefPubMed

54.

Hasslacher C, Lorenzo Bermejo J. Treatment with insulin analogs and prevalence of cardiovascular complications in patients with type 1 diabetes. Ther Adv Endocrinol Metab. 2017;8(11):149–57. https://doi.org/10.1177/2042018817732732.CrossRefPubMedPubMedCentral

Title: Advanced lipoprotein profile disturbances in type 1 diabetes mellitus: a focus on LDL particles
Authors: Antonio J. Amor
Esmeralda Castelblanco
Marta Hernández
Marga Gimenez
Minerva Granado-Casas
Jesús Blanco
Berta Soldevila
Enric Esmatjes
Ignacio Conget
Nuria Alonso
Emilio Ortega
Didac Mauricio
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Diabetes
Type 1 Diabetes
Published in: Cardiovascular Diabetology / Issue 1/2020
Electronic ISSN: 1475-2840
DOI: https://doi.org/10.1186/s12933-020-01099-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

Glucose variability and the risks of stroke, myocardial infarction, and all-cause mortality in individuals with diabetes: retrospective cohort study

Comparative effectiveness of dulaglutide versus liraglutide in Asian type 2 diabetes patients: a multi-institutional cohort study and meta-analysis

Distinct non-ischemic myocardial late gadolinium enhancement lesions in patients with type 2 diabetes

Growth differentiation factor-15 is associated with cardiovascular outcomes in patients with coronary artery disease

Association of sleep disturbance with risk of cardiovascular disease and all-cause mortality in patients with new-onset type 2 diabetes: data from the Korean NHIS-HEALS

The pro-inflammatory marker soluble suppression of tumorigenicity-2 (ST2) is reduced especially in diabetic morbidly obese patients undergoing bariatric surgery

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials